Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a drop of 33.6% from the February 13th total of 11,000 shares. Based on an average daily trading volume, of 14,300 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are sold short.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC bought a new stake in shares of Lakeshore Biopharma during the fourth quarter valued at approximately $486,000. Barclays PLC bought a new position in Lakeshore Biopharma during the third quarter valued at about $169,000. Hhlr Advisors LTD. acquired a new position in Lakeshore Biopharma during the third quarter worth about $513,000. Finally, FMR LLC bought a new position in shares of Lakeshore Biopharma during the 3rd quarter valued at about $803,000. 52.64% of the stock is owned by institutional investors and hedge funds.
Lakeshore Biopharma Stock Up 7.4 %
LSB stock traded up $0.14 during mid-day trading on Friday, reaching $2.04. The company had a trading volume of 6,868 shares, compared to its average volume of 20,002. The stock’s 50-day simple moving average is $2.45 and its two-hundred day simple moving average is $3.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.90 and a current ratio of 1.17. Lakeshore Biopharma has a one year low of $1.81 and a one year high of $11.20.
Lakeshore Biopharma Company Profile
LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.
Read More
- Five stocks we like better than Lakeshore Biopharma
- How to Calculate Stock Profit
- How to Build the Ultimate Everything ETF Portfolio
- Stock Splits, Do They Really Impact Investors?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Profit From Growth Investing
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
